FDA approves Celltrion’s biosimilar drug Remsima for sales in U.S.

Arirang News 2016-04-06

Views 2

Show more

Download

Report form

RELATED VIDEOS

FDA approves Celltrion’s biosimilar drug Remsima for sales in U.S.

play

FDA approves Celltrion’s biosimilar drug Remsima for sales in U.S.

FDA approves Celltrion’s biosimilar drug Remsima for sales in U.S.

play

FDA approves Celltrion’s biosimilar drug Remsima for sales in U.S.

U.S. FDA approves continuation of AstraZeneca's Phase III COVID-19 vaccine trials in the U.S.

play

U.S. FDA approves continuation of AstraZeneca's Phase III COVID-19 vaccine trials in the U.S.

U.S. FDA approves genetically modified salmon for human consumption

play

U.S. FDA approves genetically modified salmon for human consumption

U.S. FDA approves Moderna's COVID-19 vaccine

play

U.S. FDA approves Moderna's COVID-19 vaccine

U.S. FDA approves first antigen test kit for COVID-19

play

U.S. FDA approves first antigen test kit for COVID-19

U.S. FDA approves Moderna vaccine for emergency use

play

U.S. FDA approves Moderna vaccine for emergency use

U.S. FDA approves emergency authorization of convalescent plasma to treat COVID-19 patients

play

U.S. FDA approves emergency authorization of convalescent plasma to treat COVID-19 patients

U.S. FDA approves emergency authorization of convalescent plasma to treat COVID-19 patients

play

U.S. FDA approves emergency authorization of convalescent plasma to treat COVID-19 patients

U.S. FDA approves emergency authorization of convalescent plasma to treat COVID-19 patients

play

U.S. FDA approves emergency authorization of convalescent plasma to treat COVID-19 patients

U.S. approves additional arms sales to Taiwan worth US$ 2.37 bil.

play

U.S. approves additional arms sales to Taiwan worth US$ 2.37 bil.

U.S. State Department approves US$ 1.8 bil. in potential arms sales to Taiwan: Pentagon

play

U.S. State Department approves US$ 1.8 bil. in potential arms sales to Taiwan: Pentagon